AR and prostate cancer: Abiraterone is a CYP17A1 inhibitor (blocking both 17α hydroxylase and 17,20-lyase, two enzymes important for androgen synthesis), while enzalutamide is a potent AR ligand binding domain (LBD) competitive antagonist that blocks nuclear translocation and AR-dependent gene transcription (Charles et al., 2018; Moses et al., 2018) and demonstrated efficacy against metastatic castrated resistance prostate cancer (CRPC) and late-stage clinical trials with advanced PCa (Jung et al., 2010; Scher et al., 2010).